Moreover, as formerly mentioned, ER antagonism is a crucial therapeutic action to be considered for ER+ breast cancer treatment, reason why we postulate that CBDB and CBN might be the most promising minor phytocannabinoids for hormone-dependent breast cancer treatment, along with the major phytocannabinoid CBD. This evidence concerns the gene ESR1 and breast cancer.